Contact Sessions
James Skelley | Technology Lawyer
SESSIONS
Sessions are online meetups for discussing recent legal news, general education, and sharing various of James' research. The next scheduled session is:


You can find a complete listing of upcoming sessions and request to join HERE.
(Informal 1-2 line summaries, which certainly should not be relied upon for legal or other research purposes)
RECENT CASE HIGHLIGHTS
    • CAFC affirms IPR obviousness invalidity for claims directed "to heating, ventilation, and air conditioning (HVAC) systems." Owner makes three arguments based upon the Board's analysis, and a fourth asserting that the petition "did not disclose a sufficient obviousness theory for “detecting a manual change to the first automated setpoint” because Google relied on “general concepts” rather than a “particular example.”" CAFC resolves the first three with reference to the Board's factual findings, and the fourth in a similar manner, since the Board's analysis relied on the petition's assertion ("EcoFactor does not point out any particular deficiency in the Board’s conclusion that Ehlers and Wruck render this claim element obvious").
    • CAFC precedentially affirms nonobviousness on claims for "“dosing regimens of paliperidone palmitate” specifically to address patient noncompliance for ingesting the prior art compound ("the district court rejected Teva’s theories that a relevant artisan, in considering the prior art, would have had a motivation to combine or modify the references to arrive at the now claimed dosing regimens with a reasonable expectation of success."). CAFC's analysis here focuses on Teva's argument that "the representative claims “should be presumed obvious because they merely recite limitations from ranges disclosed in the prior art”" ("The cases that Teva invokes for this presumption, usually referred to as overlapping-range cases, are ones in which a challenged claim requires a feature in a numerical amount (specified as, e.g., a single figure or a range) and a prior-art reference teaches that feature in amounts that overlap with the claimed numerical amount. Such facts have in many cases been held sufficient to establish prima facie obviousness and, for the past two decades, to generate a presumption of obviousness."). CAFC makes this precedential to take the opportunity to tweak the DCT's analysis ("the district court erred in reading Kumar to say that the presumption is unavailable whenever there is more than one difference from the prior art."). Here, "[t]he crucial choice made by Janssen, as the district court properly framed the matter, was the choice to start with a particular high first loading dose and then follow it with a second, lower loading dose. That choice for the combination of loading doses is addressed to the relation between two dosage figures in a way that does not clearly fit within the presumption’s focus on simply selecting a number or range overlapping a prior-art range of a variable or, even, a plurality of variables that overlap with prior-art ranges where the variables are properly considered separately from each other." On this factual foundation, CAFC agrees with the DCT that the ranges-based presumption doesn't apply.
    • CAFC precedentially affirms SJ noninfringement based upon on the DCT's analysis of the evidence, rather than the claim construction, since the latter wasn't preserved for appeal ("[W]e need not resolve what to do in a case like this, where the parties present a motion for summary judgment to the district court as one involving issues of fact but it becomes clear on appeal that the motion actually turned on an unresolved issue of claim construction. This is because we will not address a claim construction issue for the first time when the appellant has failed to preserve that issue in the district court and has also failed to adequately present it to us for decision on appeal"). Ergo, CAFC considers various challenges to the jury instructions before affirming as to the whole.
    • CAFC precedentially reverses the claim construction here for the phrase "consisting essentially of" as the prosecution history argued for other than the standard interpretation ("The strongest indicators of a more-restrictive-than-typical interpretation of the phrase “consisting essentially of” are the applicant’s arguments on amendment"). Based on this new construction, CAFC likewise remands the obviousness analysis ("Under the appropriate construction of “consisting essentially of,” the claimed methods exclude compositions that contain active agents other than brimonidine, undermining the Board’s conclusion.").
    • CAFC affirms the invalidity for indefiniteness on the terms “second point”/“transition.” While straightforward, the case is mentioned here for its reliance upon Exert testimony ("We see no error in the district court crediting Mr. Gillest’s testimony over Mr. Biondich’s testimony."), notably without any witness testimony ("In this matter, we see no abuse of discretion in the district court’s proceeding to its determinations without hearing live testimony from Crown witnesses. When responding to Ball Metal’s summary judgment motion of invalidity under indefiniteness, Crown did not make a concrete case showing why such testimony was needed to resolve the remanded factual issues on indefiniteness . . . At least without a concrete showing of need, and without a concrete showing of prejudice on appeal, Crown cannot raise this issue now.").
More . . .
ABOUT
James Skelley is a solo practitioner based in Mountain View, California since 2015, focusing primarily upon technology transactions and intellectual property procurement. James' practice also serves as an "incubator" for new legal service technologies / methodologies and a "living example" of their application. To this end, James regularly partners with larger law firms and with his clients so as to improve the practice of intellectual property law.

LEGAL PRACTICE AREAS
  • Utility / Design / PCT Patent Prosecution
  • Open Source Diligence
  • Technology Transactions (typically as a team)
  • Litigation / Inter Partes Review Support (typically as a team)
  • James tends NOT to handle low-volume trademark work (though referrals are available)
LICENSING
  • USPTO - #59458 - 10/16/2006
  • California - #257829 - 12/01/2008
  • District Columbia - #1014986 - 08/05/2013
CONTACT
  • James is available by email, 8x8 hangout, and in-person meetups in the Valley.
  • Email is typically the best way to reach James.
TECHNICAL FIELDS
  • Machine Learning / Robotics
  • Cryptograpy / Cryptocurrency / Smart Contracts
  • Medical Device
  • Computational Biology (primarily modeling and proteomics)
  • Signal Processing (primarily wireless and compression)
  • Quantum Physics (primarily semiconductor) / Electromagnetics (antennae, waveguides, etc.)
  • Manufacturing / 3D Printing
  • James tends NOT to handle pure chemistry applications (though referrals are available), however James HAS handled matters involving computational proteomics, cellular modeling, and diagnostic lab protocols
SOFTWARE
LAWMUX BITES
LawMux Bites are (very) short, one-page summaries of various legal concepts, cases, and technologies. As informal summaries, you certainly shouldn't rely upon them as legal advice / for business use, but they can help orient you if you're new to the subject matter.

LAWMUX BITES
SHORT, INFORMAL NOTES
Similar to LawMux Bites, notes are (very) short writeups calling attention to various issues. As informal summaries, you certainly shouldn't rely upon them as legal advice / for business use, but they can help orient you to the relevant topic.

PAPERS / ARTICLES